Genetic screening of patients with familial hypercholesterolaemia and insurability for life-insurance policies and disability-cover policies;Actieve opsporing van patiënten met familiaire hypercholesterolemie en verzekerbaarheid voor levens- en arbeidsongeschiktheidsverzekeringen

Nederlands Tijdschrift voor Geneeskunde

Volumn 148, Issue 10, 2004, Pages 493-496

  Homsma, S J M ^a   Lansberg, P J ^b   Kastelein, J J P ^c  

^a Nationale Nederlanden NV   (Netherlands)

^b Stichting Opsporing Erfelijke H   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; BODY MASS; DNA DETERMINATION; FAMILIAL HYPERCHOLESTEROLEMIA; FINANCIAL MANAGEMENT; GENETIC SCREENING; HEALTH CARE POLICY; HUMAN; INSURANCE; LAW; MASS SCREENING; NETHERLANDS; PHENOTYPE; RISK ASSESSMENT; RISK FACTOR; SMOKING;

DNA MUTATIONAL ANALYSIS; GENETIC SCREENING; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; INSURANCE COVERAGE; INSURANCE, DISABILITY; INSURANCE, HEALTH; INSURANCE, LIFE; NETHERLANDS; PHYSICAL EXAMINATION; RISK FACTORS;

EID: 1542374224     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Lansberg PJ, Tuzgöl S, Ree MA van de, Defesche JC, Kastelein JJP. Prevalentie van familiaire hypercholesterolemie onder volwassenen in vier huisartspraktijken hoger dan werd aangenomen. Ned Tijdschr Geneeskd 2000;144:1437-40.
2. Brown MS, Goldstein JL. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle DL, Childs B, Kinzler KW, et al., editors. The metabolic and molecular bases of inherited diseases. 8th ed. New York: McGraw-Hill; 2001.
3. Fouchier SW, Defesche JC, Umans-Eckenhausen MW, Kastelein JP. The molecular basis of familial hypercholesterolemia in the Netherlands. Hum Genet 2001;109:602-15.
4. Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, Scheerder RL, Kastelein JJ. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet 2001;357:165-8.
5. Wittekoek ME, Pimstone SN, Reymer PW, Feuth L, Botma GJ, Defesche JC, et al. A common mutation in the lipoprotein lipase gene (N291S) alters the lipoprotein phenotype and risk for cardiovascular disease in patients with familial hypercholesterolemia. Circulation 1998;97:729-35.
6. Wittekoek ME, Moll E, Pimstone SN, Trip MD, Lansberg PJ, Defesche JC, et al. A frequent mutation in the lipoprotein lipase gene (D9N) deteriorates the biochemical and clinical phenotype of familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1999; 19:2708-13.
7. Tijmstra TJ. Kennis maakt verantwoordelijk. Med Contact 1997; 52:1578-81.
8. Marks D, Thorogood M, Neil HA, Wonderling D, Humphries SE. Comparing costs and benefits over a 10 year period of strategies for familial hypercholesterolaemia screening. J Public Health Med 2003;25:47-52.
9. Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HA. Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. BMJ 2002;324:1303.
10. Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HA. Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis. Health Technol Assess 2000;4:1-123.
11. Marks D, Thorogood M, Neil A, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 2003;168:1-14.
12. Loosdrecht S van de. Psychosociaal deel van het bevolkingsonderzoek naar FH. De maatschappelijke gevolgen. Amsterdam: Academisch Medisch Centrum, vakgroep Sociale Geneeskunde; 1999.
13. Vragen gesteld door leden der Kamer, vergaderjaar 1999-2000. Den Haag: SDU Uitgeverij; 2000. p. 2811-5.
14. Actuarieel Genootschap. Solidariteit verzekerd, inzicht in de solidariteit bij levensverzekeringen. AG-monografie 2. Woerden: Actuarieel Genootschap; 1997.
15. Wet Medische Keuringen. Staatsblad 1998:636.
16. Familiaire hypercholesterolemie en de wet op de medische keuringen. Publicatienr 2001/26. Den Haag: Gezondheidsraad; 2001.
17. Smilde TJ, Wissen S van, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP). Lancet 2001;357:577-81.
18. Sauvage Nolting PR de, Buirma RJ, Hutten BA, Kastelein JJ. Two-year efficacy and safety of simvastatin 80 mg in familial hypercholesterolemia. Dutch ExPRESS Investigator Group. Am J Cardiol 2002;90:181-4.
19. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423.
20. Groot E de, Jukema JW, Montauban van Swijndregt AD, Zwinderman AH, Ackerstaff RG, Steen AF van der, et al. B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings. J Am Coll Cardiol 1998;31:1561-7.
21. Umans-Eckenhausen MA, Defesche JC, Dam MJ van, Kastelein JJ. Long-term compliance with lipid-lowering medication after genetic screening for familial hypercholesterolemia. Arch Intern Med 2003; 163:65-8.
22. Wiegman A, Groot E de, Hutten BA, Rodenburg J, Gort J, Bakker HD, et al. Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. Lancet 2004;363:369-70.
23. Backer G de, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003;24:1601-10.
24. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
25. Familiaire hypercholesterolemie en verzekerbaarheid. Den Haag: Verbond van Verzekeraars; 2003.
26. Vandenbroucke JP. Screening op familiaire hypercholesterolemie. Ned Tijdschr Geneeskd 1996;140:944-8.
27. Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003;107:2409-15.